karin-thacker

Karin Thacker, MScc

Vice President, Quality and Regulatory Affairs

Ms. Thacker joined Senti in 2022 with over 20 years of leadership experience in regulatory affairs and quality assurance in the biopharmaceutical industry, ushering many novel biotherapeutics into First-in-Human clinical trials through development and approval in the US and internationally. Prior to joining Senti, she served as VP and Head of Quality and Regulatory at Harpoon Therapeutics providing regulatory and compliance oversight of their ongoing preclinical and clinical development of their suite of T cell engagers and, prior to that, as VP of Regulatory Affairs at Gritstone Bio where she built out the Regulatory Affairs function and provided regulatory strategic expertise on the development of personalized therapeutic cancer vaccines, bispecific antibodies, biomarkers, and companion diagnostics. She has also led FDA interactions on the design and quality systems, GMP bioinformatics, and manufacturing facilities. Prior to Gritstone, she served as Senior Director, Head of Regulatory Development, Global Regulatory Affairs at Puma Biotechnology. She has also held positions of increasing responsibility in regulatory Affairs and Quality at Gilead Sciences, Sunesis Pharmaceuticals, Genitope Corporation, Chiron Corporation, and Sanofi Pasteur, supporting numerous clinical development programs, product approvals, launches, and post-marketing support.

Ms. Thacker received a BSc (hons) and MSc from the University of Manitoba in Canada.